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Background: The aim of this study was to assess and compare the effective doses (ICRP 103) in the ankle region of
X-ray imaging resulting from a multi slice computed tomography (MSCT) device, two cone beam CT (CBCT) devices
and one conventional x-ray device.
Methods: Organ dose measurements were performed using 20 metal oxide field effect transistor (MOSFET)
dosimeters that were placed in a custom made anthropomorphic RANDO ankle phantom. The following scanners
were assessed in this study: Siemens Sensation Open 24-slice MSCT-scanner (120 kVp, 54 mAs), NewTom 5G CBCT
scanner (110 kVp, 2.3 - 59 mAs), Planmed Verity CBCT-scanner (90 kVp, 48 mAs), Shimadzu FH-21 HR direct
radiography equipment (AP + LAT), (57 kVp, 16 mAs).
Results: Measurements of the MSCT device resulted in 21.4 μSv effective dose. The effective doses of CBCTs were
between 1.9 μSv and 14.3 μSv for NewTom 5G and 6.0 μSv for Planmed Verity. Effective doses for the Shimadzu
FH-21 HR conventional radiography were 1.0 μSv (LAT) and 0.5 μSv (AP), respectively.
Conclusions: Compared with a conventional 2D radiographic device, this study showed a 14-fold effective dose for
standard MSCT and 1.3 -10 fold effective dose for standard CBCT protocols. CBCT devices offers a 3D view of ankle
imaging and exhibited lower effective doses compared with MSCT.
Keywords: X-ray imaging, CBCT, Organ dose, Effective doseBackground
Fractures of the foot are very common and account for
approximately 10% of all fractures inflicted on the body
[1]. Common causes of fractures of the foot are falling
from heights and vehicle accidents [2]. The most com-
monly fractured foot bone is the calcaneus and accounts
for approximately 60% of all foot fractures [3]. Talus
fractures are the second most common fractures in the
foot area and occur in 3-6% of cases [4]. To date, con-
ventional radiographs have played a key role in the pri-
mary assessment of such fractures and provide quick,
cheap and low-dose images. However, in complex frac-
ture cases, conventional radiographs have limitations in
their dynamic range and image contrast. Furthermore in* Correspondence: juha.koivisto@planmeca.com
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unless otherwise stated.conventional radiographs the object of interest can be
obscured by overlying structures [5].
In many hospitals, multi-slice computed tomography
(MSCT) technology has completely replaced conven-
tional radiography providing all the necessary informa-
tion in one examination that formerly required multiple
studies [6]. The great benefits of 3D imaging devices are,
however, often associated with a disproportional increase
in radiation dose, an increase in part attributed to over-
utilization [7] without taking the ALARA (As low as rea-
sonable achievable) principle into account [8].
One method of minimizing radiation doses in 3D im-
aging of the foot and ankle is to implement cone-beam
computed tomography (CBCT) technology. CBCT tech-
nology has only recently been applied for the imaging of
extremities such as the foot, ankle, knee, wrist and
shoulder, and offers high spatial resolution, easy installa-
tion and low radiation dose [9-11] at a lower cost whenl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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novel CBCT devices offer the possibility of imaging
the lower extremities under weight-bearing conditions
(patient in standing position) and subsequently offers new
possibilities to study osseous changes, for instance, degen-
erative joint disease of the knee, ankle and foot [13]. Both
MSCT and CBCT are known to produce higher levels of
radiation when compared with the conventional X-ray de-
vices that were previously used. This has aroused a grow-
ing interest in effective dose measurements that have been
commonly conducted using the CT dose index (CTDI)
method [14,15] or by using optically stimulated lumines-
cence (OSL) dosimeters [9]. The aim of this study was
to assess the organ and effective doses International
Commission on Radiological Protection (ICRP 103) [16]
in the ankle area for two newly introduced CBCT devices,
and to compare the corresponding MSCT and conven-
tional radiography doses using metal oxide field effect
transistor (MOSFET) dosimeters.
Methods
X-ray devices
Effective doses were calculated form organ doses ob-
tained on one MSCT device, two CBCT devices and one
conventional radiographic device: Siemens Sensation
Open 24-slice scanner (Siemens, Forchheim, Germany),
Planmed Verity CBCT-scanner (Figure 1A) (Planmed
Oy, Helsinki, Finland), NewTom 5G CBCT scanner
(Figure 1B) (NewTom 5G®, QR, Verona, Italy) and
Shimadzu FH-21 HR direct digital radiography equipment
(Shimadzu Corporation, Kyoto, Japan).
In order to attain comparative measurements, the
MSCT scan length and the conventional X-ray field size
were matched to the NewTom 5G (180 mm) and Planmed
Verity (160 mm) scan lengths. In addition the “12 × 8 cm”
FOV was measured using the HiRes modality and the
“15 × 12 cm” FOV was measured using the standard scan
modality. The small “12 × 8 cm” FOV using “HiRes” scanFigure 1 The measurement setup for the Planmed Verity CBCT scannof NewTom 5G was measured as it provided comparable
mAs values to MDCTand Planmed Verity CBCT device.
Since ankle fractures are typically imaged using anterior-
posterior (AP) and lateral (LAT) radiographic views, the
sum doses obtained using both projections were used as a
reference in the dose comparison. All measurements were
performed using manufacturer recommended ankle exam-
ination mode and exposure parameters (Table 1). The
NewTom 5G CBCT scanner, however, employs automatic
exposure control where the mA is set based on patient
size estimated from two scout images. Here the mA can-
not be changed manually.
Phantom
All dose measurements were performed on a custom
made anthropomorphic RANDO leg phantom (Radiation
Analogue Dosimetry System; The Phantom Laboratory,
Salem, NY, USA). The phantom comprised human leg
bones molded in a soft tissue-equivalent material to
match the attenuation and scattering properties of the
bone and soft tissues of the human leg. The ankle
area consisted of six layers numbered from 23 to 28
(Figure 2). Predrilled holes for the MOSFET dosime-
ters in each layer were arranged in a 1.5 cm × 1.5 cm
matrix. The holes were delivered with factory fitted
soft tissue equivalent plugs that were subsequently re-
moved and replaced with MOSFET dosimeters. All
ankle organ dose measurements were performed by
directing the beam to layers 24–28 in the RANDO
phantom (Figure 2). The phantom leg was positioned
vertically in the MDCT and Planmed Verity CBCT
device. However due to a different ankle support con-
figuration and lack of space for the dosimeter cables
on the NewTom 5G device a horizontal phantom pos-
ition was used. This difference in positioning did
however not affect the effective dose measurement
due to the 360° gantry scan angle used on the NewTom
5G device. In total, between four to ten exposures wereer (A) and the NewTom 5G CBCT scanner (B).
Table 1 Exposure parameters of the CBCT and MSCT scanners and conventional X-ray devices
Siemens NewTom 5G Planmed Shimadzu
Somatom CBCT Planmed FH-21 HR
Definition AS+ Hi Res Standard Standard Verity AP + LAT
MSCT “12 × 8” “15 × 12” “18 × 16” CBCT Radiography
Potential (kV) 120 110 110 110 90 57
Tube current (mA)‡ 54 11 1,5 0,6 8 -
Exposure time (s) 1.0 5,4 3,6 3,6 6 -
Q (mAs) 54 59 5,3 2,3 48 16
Slice thickness (mm) 0.6 - - - - -
Pitch (mm) 0.5 - - - - -
Voxel H (mm) - 0.15 0.3 0.3 0.2 -
Voxel L (mm) - 0.15 0.3 0.3 0.2 -
Voxel W (mm) - 0.15 0.3 0.3 0.2 -
Scan angle 360° 360° 360° 360° 210° -
Frame number - 360 360 360 300 -
Scan FOV (mm)† 130 × 160 120 × 80 150 × 120 180 × 160 130 × 160 130 × 160
†For MSCTs and CBCT: diameter × length, for conventional X-ray width × height.
‡For NewTom 5G CBCT: mA is automatically adjusted using the “SafeBeam™” acquisition option.
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the mAs of the device used, and the sum of all exposures
was averaged.
MOSFET dosimeters
All organ dose measurements in the ankle and foot region
were performed using the same MOSFET dosimeters that
were connected to a mobile TN-RD-70-W20 MOSFET
device. The device comprised one TN-RD-38 wireless
Bluetooth transceiver, four TN-RD-16 reader modules,
twenty high-sensitivity TN-1002RD-H detectors and TN-
RD-75 M software (Best Medical, Canada). The dosimeters
can be used in either a high or low bias voltage providing
high or low sensitivity response, respectively. In this study,
all measurements were performed using the high bias volt-
age setting to achieve the best accuracy. Prior to the mea-
surements, the mobile MOSFET device was calibrated
using a RADCAL 1015 dosimeter and a RADCAL 10X5-6
ionization chamber (Radcal Corporation, Monrovia, CA,
USA) that were referenced to the secondary standardFigure 2 The x-ray source, 3D FOV and ankle layers of the anthropomdosimetry laboratory (SSDL) at the Finnish Radiation and
Nuclear Safety Authority (STUK) that is traceable to pri-
mary standard dosimetry laboratory (PSDL). The dosimeter
calibration procedure and angular sensitivity divergences
and their implications were taken into consideration based
on the results of an earlier study by Koivisto et al. [17].
Furthermore, the energy dependence of MOSFET dosime-
ters was considered to be negligible based on a study by
Bower et al. [18].
The twenty MOSFET dosimeters (Figure 3, Table 2)
were meticulously placed into layers 23–28 of the phan-
tom to cover the most radiosensitive organs such as
bone marrow and remainder tissues [16]. Since the lar-
gest contribution to the effective dose in the ankle area
is caused by the bone marrow, one dosimeter was placed
in the marrow of each layer to provide accurate bone
marrow dose detection. Nine bone marrow dosimeters
were placed inside the tibia, fibula, navicular, talus and
calcaneus. Furthermore, four dosimeters were placed in
the muscle area, two dosimeters in the lymphatic nodes,orphic RANDO phantom used in this study.
Figure 3 The placement of MOSFET dosimeters in the leg phantom (AP (A), LAT B).
Koivisto et al. Journal of Foot and Ankle Research  (2015) 8:8 Page 4 of 10two dosimeters in the skin and two on the bone surface.
The method presented in this study takes into account vari-
ous depths within the phantom and the organ point doses
on the skin (Figure 3). This was done to overcome the
problems related to the non-uniform dose profiles pro-
duced by the MSCT and CBCT devices. MOSFET dosime-
ters were chosen for this study as they provide a nearly
real-time dose assessment and have been found appropriateTable 2 MOSFET dosimeter location in RANDO leg
phantom
Dosimeter
no. Layer Location Tissue
1 23 Tibia Bone Marrow
2 23 Peroneus brevis Muscle
3 23 Gastrocnemius Muscle
4 24 Tibia Bone Marrow
5 24 Tibialis anterior Muscle
6 25 Fibula Bone marrow
7 25 Tibia Bone marrow
8 26 Superior extensor Retinaculum Skin
9 26 Tibia Bone marrow
10 26 Calcaneal tendon Skin
11 26 Fibula Bone marrow
12 26 Lymp.vein Lymphatic nodes
13 27 Posterior calcaneal tuberosity Bone surface
14 27 Navicular Bone marrow
15 27 Talus Bone marow
16 28 Metatarsals Bone marrow
17 28 Lymp.vein Lymphatic nodes
18 28 Calcaneus Bone marrow
19 28 Calcaneal tuberosity Bone surface
20 28 Flexor digitorum brevis Musclefor extremity dose assessment in a previous study [17] and
to provide TLD and Monte Carlo simulation comparable
results according to earlier studies [19,20].
The equivalent dose or radiation-weighted dose HT for
all organs or tissues T was calculated using the following
equation [21,22]:
HT ¼ wR
X
i
f i⋅DTi ð1Þ
where the radiation weighing factor wR = 1
. (Sv/Gy) for
x-rays, fi the mass fraction of tissue T in layer i, and DTi
being the average absorbed dose of tissue T in layer i.
In this study, the term fraction irradiated (fi) used
below describes the exposed and dosimetrically evalu-
ated coverage of each studied organ in relative scale
(Table 3). The studied organs were exposed to direct or
scattered radiation during the scans.Bone marrow
Bone marrow is one of the largest anatomical structures
in the body and represents 4% of the total body mass
[23]. The bone marrow mass fraction used in this study
was based on the results of two previous studies by
Fuller et al. [24] and Les et al. [25]. Fuller et al. mea-
sured the bone marrow volume in the thigh and calf area
using MRI data. According to their calculations, it was
estimated that 100 mm sections of tibia and fibula con-
tained 0.7% of whole body mass bone marrow. Further-
more, Les et al. [25] calculated the bone marrow content
of the foot and ankle region using human cadavers and
estimated that the structures contained 0.4% of the
whole body mass bone marrow. When combining the
results of both studies, a total of 1.1% of the bone mar-
row mass is contained in the ankle area of the examined
phantom.
Table 3 ICRP 103 tissue weighting factors (wT), fractions
irradiated (fi) and dosimeters used to calculate effective
dose
Dosimeter
Organ wT fi number
Bone marrow 0.12
Tibia 0.007 1, 4, 7, 9
Fibula 0.001 6, 11
Navicular 0.001 14
Metatarsals 0.001 16
Calcaneus 0.002 18
Bone surface 0.01
Calcaneal tuberosity 0.049 13, 19
Skin 0.01
Superior extensor Retinaculum 0.009 8
Calcaneal tendon 0.026 10
Remainder 0.12
Lymphatic nodes 0.010 10, 14, 15
Muscle 0.009 2, 3, 5, 20
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The bone surface in the ankle region was estimated based
on the bone surface-to-volume ratio presented in ICRP 70
[26], and the percentage of total skeletal mass fraction
contributed by the exposed bones according to ICRP 89
[27]. The bone surface in the examined region was esti-
mated to represent 4.9% of the full body bone surface.
Skin
The skin area in the calf and ankle region on layers 23–26
was calculated using the perimeter of each layer multiplied
by layer thickness (25 mm). The skin area in foot region
layers 27–28 was assessed with a simple planimetric
method consisting of placing transparent film on the target
and then measuring the area that the film covered. The
total body skin area was calculated using the Du Bois-Du
Bois formula [28]. The skin of phantom layers 23–28 was
estimated to represent 3.5% of the whole body skin area.
Remainder tissues
Muscles and lymphatic nodes are the only organs in the
leg that are included in the remainder tissues defined by
ICRP 103 [16].
Muscles
The total body muscle mass is estimated to weigh
28.000 g [29,30]. The assessment of muscle volume in
the ankle and foot was based on a lower extremity prop-
erty study by Ward et al. [31]. The sum of the muscle
fractions contained in the examined volume was esti-
mated to represent 0.9% of total body muscle mass.Lymphatic nodes
According to a whole-body lymphoscintigraphy examin-
ation performed at the Docrates Cancer Center in
Helsinki, Finland, it was estimated that one ankle contains
1% of the lymphatic nodes of the whole body.
The effective dose was obtained from measured organ
doses using the guidelines given by the International Com-
mission on Radiological Protection (ICRP 103) [16]. The ef-
fective dose E is calculated by the following equation:
E ¼
X
T
wT ⋅HT ; ð2Þ
where wT is the weighting factor of tissue T and HT is
the equivalent dose in tissue T. According to the ICRP
recommendation, the calculation of effective dose is
based on a large number of organs and tissues in the
body and the sum of the weighting factors wT is 1. Mus-
cles and lymphatic nodes are grouped in the calculation
as “remainder tissues”. The wT for the remainder tissues
specified by ICRP 103 is 0.12.
The equivalent dose in the bone marrow and the bone
surface was calculated by averaging the equivalent doses of
the corresponding dosimeters representing the organ. Fi-
nally, the contribution to the effective dose was calculated
using specific fractions irradiated and weighting factors.
The ICRP 103 weighting factors wT and the fraction of ir-
radiation used in the calculations are shown in Table 3.Results
Siemens sensation open MSCT device
The effective dose attained using the MSCT device was
21.4 μSv. The highest contributor to the effective dose
was bone marrow (44%) followed by bone surface (34%),
skin (15%), lymphatic nodes (4%) and muscles (3%).NewTom 5G CBCT device
The effective dose obtained using the NewTom 5G CBCT
device with three different FOVs including the default
ankle settings and automatic dose control. Using the 15 ×
12 cm FOV with the “standard dose” setting the effective
dose was 4.0 μSv. The contributors to the effective dose
were as follows: bone surface (30%), bone marrow (44%),
skin (19%), lymphatic nodes (5%) and muscles (1%). Using
the 18 × 16 cm FOV with the “standard dose” setting the
effective dose was 1.9 μSv. The contributors to the effect-
ive dose were as follows: bone surface (32%), bone marrow
(43%), skin (17%), lymphatic nodes (5%) and muscles (3%).
Using the 12 × 8 cm FOV with the “High-Res” setting the
effective dose was 14.3 μSv. The contributors to the effect-
ive dose were as follows: bone surface (51%), bone marrow
(27%), skin (16%), lymphatic nodes (5%) and muscles (1%).
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The effective dose attained on the Planmed Verity CBCT
device using the default “medium” ankle settings was
6.0 μSv. The major contributors to the effective dose were
bone marrow (45%), bone surface (33%), skin (15%),
lymphatic nodes (6%) and muscles (1%).
Shimadzu FH-21 HR conventional radiography device
The effective doses attained using conventional radiography
were 0.5 μSv in the anterior-posterior (AP) position and
1.0 μSv in the lateral position (LAT). Most standard diag-
nostic procedures comprise both AP and LAT exposures.
The sum dose was 1.5 μSv and the bone marrow was the
highest contributor (49%) followed by bone surface (23%),
skin (18%), lymphatic nodes (6%) and muscles (4%).
The effective doses and dose contribution of each organ
are shown in Table 4. The sagittal projections (cropped
images) of the exposed volume using conventional radiog-
raphy, two CBCT and MSCT devices excluding toes are
presented in Figure 4.
Organ and effective dose uncertainty
The type A standard (1SD) uncertainties of the absorbed
organ doses were evaluated according to a previous study
[15]. The calculated statistical dosimeter uncertainties
were as follows (Table 5): Siemens Sensation Open (3-5%),
NewTom 5G: “12 × 8 cm” FOV (4-33%) (Table 5),
NewTom 5G: “15 × 12 cm” FOV (7-17%), NewTom 5G:
“18 × 16 cm” FOV (12-23%), Planmed Verity (5-34%) and
Shimadzu FH-21 HR (9-26%). The uncertainties of the
point dose measurements were evaluated as the weighted
sum of variances and included the statistical measurement
error according to a previous investigation [32], un-
certainties from the phantom and dosimeter position-
ing (10%, 10%), x- ray source variation (5%) [19] and
cable irradiation uncertainties (1%) [33]. Regardless
of the individual point dose variations (Table 5) and
the other sources of uncertainties the overall impactTable 4 Equivalent dose contributions and effective doses (μS
radiography devices
Siemens NewTom 5G
Sensation CBCT
Open Hi Res Sta
MSCT “12 × 8” “15
Bone marrow 9.5 3.9 1.8
Bone surface 7.2 7.3 1.2
Skin 3.1 2.2 0.7
Remainder
Lymphatic nodes 0.9 0.8 0.2
Muscles 0.6 0.1 0.1
Effective dose 21.4 14.3 4.0of one dosimeter on the effective dose was negligible.
The combined uncertainties (uc) for a single dosimeter
were as follows: Siemens Sensation Open (15-16%),
NewTom 5G: “12 × 8 cm” FOV (16-36%), NewTom 5G:
“15 × 12 cm” FOV (17-23%), NewTom 5G: “18 × 16 cm”
FOV (12-23%), Planmed Verity (16-37%) and Shimadzu
FH-21 HR (17-30%). The tissue dose uncertainty depends
on the dosimeter uncertainty and the assessed uncer-
tainty of the irradiated tissue fraction fi (25%). The tissue
dose uncertainties attained using e.g. the NewTom 5G
CBCT device (12 × 8 cm FOV) was as follows: bone mar-
row (14%), bone surface (29%), skin (26%) and remainder
tissues (19%).
The expanded (2SD) combined effective dose uncertain-
ties (Uc) were calculated as a weighted sum of variances of
bone marrow, bone surface, and skin and remainder tissue
doses according to a previous study [17]. This resulted in
23% for the Siemens Sensation Open MSCT device, 32%
for the NewTom 5G device, 23% for the Planmed Verity
device and 21% for the Shimadzu FH-21 HR device.
Discussion
In this study, the organ and effective doses in the ankle
area were evaluated on one MSCT device, two CBCT de-
vices and one radiographic device. The organ dose mea-
surements were performed using an anthropomorphic
ankle phantom and twenty MOSFET dosimeters posi-
tioned in the most radiosensitive areas. The effective doses
of the NewTom 5G and Planmed Verity ankle imaging
CBCT modalities have not previously been presented.
The highest effective dose (21.4 μSv) was attained
using the Siemens Sensation Open MSCT device. The
dose was 14 times higher than the dose attained using
the conventional device. The effective dose attained
using the NewTom 5G CBCT device was 4.0 μSv using
the “Standard dose” setting and 15 × 12 cm FOV. This
resulted in 1.7 times higher dose than the conventional
device. Furthermore the 16 × 18 cm FOV using thev) attained in the ankle region using MSCT, CBCT and
Shimadzu
Planmed FH-21 HR
ndard Standard Verity X-ray
× 12” “18 × 16” CBCT AP+LAT
0.8 2.7 0.7
0.6 1.9 0.3
0.3 0.9 0.3
0.1 0.3 0.1
0.1 0.1 0.1
1.9 6.0 1.5
Figure 4 Sagittal ankle projections using the Shimadzu FH21-HR radiography device (A), the Siemens Sensation Open MSCT device (B),
the NewTom 5G CBCT device (18 × 16 cm FOV) (C) and the Planmed Verity CBCT device (D).
Table 5 Average and (1SD) variation based on six absorbed dose meausurements and combined point dose uncertainty
for twenty dosimeters with NewTom 5G (12 × 8 cm FOV)
Dosimeter location Dosimeter Measured Dose Point dose
in phantom no. dose (mGy) uncertainty (%) uncertainty (%)
Tibia 1 0.25 33% 36 %
Peroneus brevis 2 0.33 27% 31 %
Gastrocnemius 3 0.52 20% 25 %
Tibia 4 0.48 22% 26 %
Tibialis anterior 5 0.53 20% 25 %
Fibula 6 0.73 17% 22 %
Tibia 7 0.81 16% 22 %
Superior extensor Retinaculum 8 3.86 7% 16 %
Tibia 9 4.04 7% 16 %
Calcaneal tendon 10 7.11 5% 16 %
Fibula 11 6.53 5% 16 %
Lymp.vein 12 10.4 4% 16 %
Posterior calcaneal tuberosity 13 7.71 5% 16 %
Navicular 14 4.09 7% 16 %
Talus 15 4.66 6% 16 %
Metatarsals 16 4.25 6% 16 %
Lymp.vein 17 6.15 5% 16 %
Calcaneus 18 6.45 5% 16 %
Calcaneal tuberosity 19 7.33 5% 16 %
Flexor digitorum brevis 20 3.40 7% 17 %
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than the dose attained using the conventional x-ray de-
vice. The effective dose of the NewTom 5G CBCT de-
vice using the “High-Res” mode and 12 × 8 cm FOV
(14.3 μSv) was the 9.6 times the dose of a conventional
device but still 33% lower when compared to the MSCT.
The dose for Planmed Verity (6.0 μSv) was four times
higher than that of conventional radiography, but less
than one third of the MSCT dose”.
The CBCT devices evaluated in this study demonstrated
significantly lower effective doses when compared with
the MSCT device. However, even lower doses were ac-
quired using the conventional 2D radiography device.
Interestingly, the two CBCT devices in this study differed
in kV and FOV settings. The Planmed Verity CBCT device
provides only one (13 × 16 cm) FOV. The effective doses
were measured for Planmed Verity retrospectively using
lower kVps with the default 48 mAs setting, resulting as
follows: 3.9 μSv (80 kVp), 4.8 μSv (84 kVp), 5.3 μSv (88
kVp). The NewTom 5G device did not offer possibilities
to change the tube voltage, and it is fitted with a “Safe
Beam” automatic exposure control that adjusts the tube
current (mA) based on scout images according to factory
preset dose levels. The NewTom 5G device, however, al-
lows the user to select from three different fields of view
(12 × 8 cm, 15 × 12 cm and 18 × 16 cm) that were also in-
vestigated. The “Safe Beam” setting resulted in a much
higher dose (14.3 μSv) than those attained on the Planmed
Verity device even though a much smaller (12 × 8 cm)
FOV with “HiRes” option was used. However, when larger
FOVs with “Standard” option were used on the NewTom
5G device, in the effective doses were registered (110
kVp): 4.0 μSv for 15 cm × 12 cm FOV (5.3 mAs) and
1.9 μSv for 18 cm × 16 cm FOV (2.3 mAs). The reduction
in the effective dose using larger FOVs could have been
caused by the use of the “Standard” option that reduces
the mAs. Furthermore, when using the larger FOVs the
scout images were larger than the phantom, resulting in
an underestimation of the patient attenuation thus yield-
ing to smaller mAs. Presumably this does lead to a reduc-
tion in image quality, but it may still provide adequate
diagnostic quality.
In a recent study, Ludlow et al. evaluated the effective
doses in the foot and ankle area using a conventional
radiographic (Siemens) device, a 3D MDCT (Siemens
Definition) device and a CBCT (PedCAT) device [7]. The
resulting effective doses were 0.6 μSv for the radiographic
device, 23 μSv for the MSCT device (120 kVp, 100 mAs)
and 1.4 μSv for the CBCT device (100 kVp, 4.5 mAs). The
differences in the results compared to those of this study
could have been caused by a number of potential differ-
ences between the study designs. These include the differ-
ent field of view, manufactures’ X-ray spectra, exposure
parameters, mAs’s, and the bone surface, skin and muscleorgan compositions used by Ludlow et al. The major dif-
ference between our studies is that the lymphatic nodes
and bone marrow structures were included in our study,
as proposed by Fuller and Les et al., while they were not
included in the study by Ludlow et al. since their bone
marrow content was based on the old model by Cristy
et al. [34]. According to Cristy et al., there is no active
bone marrow in the lower adult extremities. According to
Fuller et al. [24], however, 10 cm of the calf section (tibia,
fibula) contains 20 cm3 of bone marrow. According to
McGlamry et al. [35], the proximal tibia has been the most
frequently used location to extract bone marrow in vol-
umes between 30–40 cc. Moreover, Les et al. [25] ex-
tracted up to 6 cc bone marrow from the calcaneus and,
according to Schweinberger et al. [36], the calcaneus and
proximal tibial metaphysis offer a significant amount of
bone marrow. In contrast to Ludlow’s study, our study in-
cluded the bone marrow, which was the major contributor
to the effective dose. When the bone marrow contribu-
tions were extracted from our results and the mAs’ were
scaled to match those of Ludlow et al. the differences be-
tween the two studies were less than 20%. The differences
were small considering the variations in FOVs, X-ray spec-
tra, exposure parameters, phantom tissue composition
and measurement methods.
Earlier, Huda et al. [37] assessed the effective dose in the
ankle region using conventional radiography (70 kVp, 10
mAs). They observed a 0.72 μSv upper limit of the effect-
ive dose. The differences in the doses were caused by the
number of projections taken. Namely, in this study AP+
LAT projections were taken while in the study by Huda
et al. only one exposure was performed. Furthermore, in a
study by Cross et al. [38], the effective dose and radiation
risk associated with ionizing radiation in sports medicine
were investigated. According to their findings, the effective
dose for common radiographic procedures in the ankle
and foot area resulted in a higher (4 μSv) dose than that
attained in this study.
In a previous study, Biswas et al. investigated the radi-
ation exposure from musculoskeletal computed tomog-
raphy scans. In their study, the imaging parameters were
recorded and calculator software was used to attain the ef-
fective doses according to a protocol derived from publica-
tion SR250 of the National Radiological Protection Board
of the United Kingdom [39]. Tube voltage and tube
current (mean ± SD) were 120 kVp and 143 ± 91 mA
(mean ± SD), respectively. According to their study, the ef-
fective dose resulting from the ankle scan was 70 μSv. Our
effective dose result was one third of that obtained by
Biswas et al.
All effective doses were evaluated in this study based on
manufacturer recommendations and, therefore, the results
of this study should be interpreted with caution. A further
limitation of this study is the lack of image quality
Koivisto et al. Journal of Foot and Ankle Research  (2015) 8:8 Page 9 of 10assessment that is essential when choosing the appropriate
exposure parameters. Another setback of this study is the
lack of clinical evaluation of the different imaging modal-
ities. Nevertheless all CBCT volumes in this study were re-
constructed with smaller voxel sizes than those used on the
MDCT device. The smaller voxel size can be an advantage
in the detection of non-displaced fractures in clinical set-
tings. On the other hand, CBCT devices have a higher
noise and lower contrast-to-noise ratio than MDCT de-
vices. This might be a disadvantage in the delineation of
fractures. Nevertheless in such cases the use of a MDCT
device could be advantageous despite of the higher effective
dose induced.
A further drawback of this study was the lack informa-
tion on the quantification of the proportions of red and
yellow bone marrow in the ankle region; this study as-
sumes 100% red bone marrow and no yellow bone mar-
row, possibly leading to an overestimation of the effective
dose. Another source of error in this study could be the
use of two projections instead of the three projections rec-
ommended by ACR [40] in conventional radiography (AP,
LAT, (mortise) oblique projections).
The setback of MOSFET dosimeters is that they are
not tissue equivalent and become visible on the radio-
graphs. In this study the exposures were, however, taken
only to evaluate the effective dose and thus the visibility
of the MOSFET dosimeters in the images were not con-
sidered problematic.
Conclusions
Compared with the conventional 2D radiographic de-
vice, this study showed a 14-fold effective dose for a
standard MSCT protocol and between a 1.3-4 fold ef-
fective dose for standard CBCT protocols The results of
this study showed a large variability in the effective dose
values attained on the CBCT devices using different scan
modes and FOVs. Furthermore, when compared with
MSCT devices, the two CBCT devices assessed in this
study offer a promising low-dose, three-dimensional al-
ternative for ankle imaging.
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